L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia

Aim: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracycline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumulative doses from 100 to 200 mg/m2. Material...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2017
Hauptverfasser: Skrypnyk, I., Maslova, G., Lymanets, T., Gusachenko, I.
Format: Artikel
Sprache:English
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2017
Schlagworte:
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/138547
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia / I. Skrypnyk, G. Maslova, T. Lymanets, I. Gusachenko // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 308–311. — Бібліогр.: 12 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-138547
record_format dspace
spelling Skrypnyk, I.
Maslova, G.
Lymanets, T.
Gusachenko, I.
2018-06-19T09:15:18Z
2018-06-19T09:15:18Z
2017
L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia / I. Skrypnyk, G. Maslova, T. Lymanets, I. Gusachenko // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 308–311. — Бібліогр.: 12 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/138547
Aim: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracycline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumulative doses from 100 to 200 mg/m2. Materials and Methods: A total of 81 adult AL patients (38 males and 43 females with the age of 16–59 years) were studied. The patients were divided into two groups: group I (n = 34), AL patients treated with chemotherapy (CT) and L-arginine hydrochloride; group II (n = 47) — AL patients treated with CT only. Cardiac evaluation and endothelial function assessment were performed at baseline and after second CT. Electrocardiography (ECG) parameters, lipid peroxidation activity, antioxidant protection and NO system state were evaluated. Results: The bioelectric activity abnormalities of the myocardium were observed in studied patients with low cardiac risk after induction CT. In case of L-arginine administration, only minimal daily ECG changes were recorded. A significant difference in the lipid peroxidation and antioxidant defense system activity in patients of groups I and II was determined. We noticed deepening of endothelial dysfunction on the background of cytostatic therapy with anthracycline antibiotics compared with baseline values in patients of group II. It was found that prophylactic L-arginine increases superoxide dismutase level and reduces the total NOS activity due to its inducible isoform. Conclusion: The leading factor of anthracycline-induced cardiotoxicity is the imbalance between free radical generation and their inactivation that leads to endothelial dysfunction development. L-arginine eliminates the prooxidant-antioxidant imbalance and improves the endothelial function.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
spellingShingle L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
Skrypnyk, I.
Maslova, G.
Lymanets, T.
Gusachenko, I.
Original contributions
title_short L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
title_full L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
title_fullStr L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
title_full_unstemmed L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
title_sort l-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia
author Skrypnyk, I.
Maslova, G.
Lymanets, T.
Gusachenko, I.
author_facet Skrypnyk, I.
Maslova, G.
Lymanets, T.
Gusachenko, I.
topic Original contributions
topic_facet Original contributions
publishDate 2017
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracycline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumulative doses from 100 to 200 mg/m2. Materials and Methods: A total of 81 adult AL patients (38 males and 43 females with the age of 16–59 years) were studied. The patients were divided into two groups: group I (n = 34), AL patients treated with chemotherapy (CT) and L-arginine hydrochloride; group II (n = 47) — AL patients treated with CT only. Cardiac evaluation and endothelial function assessment were performed at baseline and after second CT. Electrocardiography (ECG) parameters, lipid peroxidation activity, antioxidant protection and NO system state were evaluated. Results: The bioelectric activity abnormalities of the myocardium were observed in studied patients with low cardiac risk after induction CT. In case of L-arginine administration, only minimal daily ECG changes were recorded. A significant difference in the lipid peroxidation and antioxidant defense system activity in patients of groups I and II was determined. We noticed deepening of endothelial dysfunction on the background of cytostatic therapy with anthracycline antibiotics compared with baseline values in patients of group II. It was found that prophylactic L-arginine increases superoxide dismutase level and reduces the total NOS activity due to its inducible isoform. Conclusion: The leading factor of anthracycline-induced cardiotoxicity is the imbalance between free radical generation and their inactivation that leads to endothelial dysfunction development. L-arginine eliminates the prooxidant-antioxidant imbalance and improves the endothelial function.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/138547
citation_txt L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia / I. Skrypnyk, G. Maslova, T. Lymanets, I. Gusachenko // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 308–311. — Бібліогр.: 12 назв. — англ.
work_keys_str_mv AT skrypnyki larginineisaneffectivemedicationforpreventionofendothelialdysfunctionapredictorofanthracyclinecardiotoxicityinpatientswithacuteleukemia
AT maslovag larginineisaneffectivemedicationforpreventionofendothelialdysfunctionapredictorofanthracyclinecardiotoxicityinpatientswithacuteleukemia
AT lymanetst larginineisaneffectivemedicationforpreventionofendothelialdysfunctionapredictorofanthracyclinecardiotoxicityinpatientswithacuteleukemia
AT gusachenkoi larginineisaneffectivemedicationforpreventionofendothelialdysfunctionapredictorofanthracyclinecardiotoxicityinpatientswithacuteleukemia
first_indexed 2025-12-01T10:50:39Z
last_indexed 2025-12-01T10:50:39Z
_version_ 1850859948210126848